Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases

J Gastroenterol Hepatol. 1993 Sep-Oct;8(5):437-41. doi: 10.1111/j.1440-1746.1993.tb01544.x.

Abstract

Serum levels of the tissue inhibitor of metalloproteinases-1 (TIMP-1) were measured in 268 patients with liver diseases by means of a one-step sandwich enzyme immunoassay. In the cases of acute hepatitis, chronic active hepatitis (CAH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), the levels of TIMP-1 were higher than those of the control group. Tissue inhibitor of metalloproteinases-1 levels correlated with type III procollagen peptide and with type IV collagen, indicating TIMP-1 as a useful marker for hepatic fibrosis. Levels of TIMP-1 also correlated with aspartate aminotransferase and alanine aminotransferase levels and showed the highest levels in acute hepatitis. Thus, TIMP-1 might also reflect hepatic inflammation. Serum levels of alpha-fetoprotein and TIMP-1 had a significant positive correlation in patients with HCC. A cut-off level of TIMP-1 between LC and HCC was set at 440 ng/mL, having a low sensitivity and a high specificity. These results suggest the usefulness of TIMP-1 as a tumour marker in cases of HCC where alpha-fetoprotein levels are not elevated.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Fatty Liver / blood
  • Female
  • Glycoproteins / blood*
  • Hepatitis, Viral, Human / blood
  • Humans
  • Liver Cirrhosis / blood
  • Liver Diseases / blood*
  • Liver Diseases / diagnosis
  • Liver Neoplasms / blood
  • Liver Neoplasms / diagnosis
  • Male
  • Matrix Metalloproteinase Inhibitors*
  • Middle Aged
  • Sensitivity and Specificity
  • Tissue Inhibitor of Metalloproteinases

Substances

  • Biomarkers, Tumor
  • Glycoproteins
  • Matrix Metalloproteinase Inhibitors
  • Tissue Inhibitor of Metalloproteinases